PDF herunterladen
Arzneimittelforschung 2011; 61(1): 61-65
DOI: 10.1055/s-0031-1296168
Antibiotics · Antimycotics · Antiparasitics · Antiviral Drugs · Chemotherapeutics · Cytostatics
Editio Cantor Verlag Aulendorf (Germany)

Bioequivalence study of levofloxacin tablets in healthy Indian volunteers using HPLC

Ayan Das
1   Bioequivalence Study Centre, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India
,
Jayanti Mukherjee
1   Bioequivalence Study Centre, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India
,
Goutam Dey
1   Bioequivalence Study Centre, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India
,
Amlan K Sarkar
1   Bioequivalence Study Centre, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India
,
Bijoy K Sahoo
1   Bioequivalence Study Centre, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India
,
Uday S Chakrabarty
1   Bioequivalence Study Centre, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India
,
Utpal Nandi
1   Bioequivalence Study Centre, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India
,
Tapan K Pal
1   Bioequivalence Study Centre, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
28. November 2011 (online)

    Lizenzen und Reprints

Abstract

An improved HPLC method was developed and validated for the determination of concentration of levofloxacin (CAS 100986-85-4) in human plasma. This paper is an attempt to compare the bioavailability of two levofloxacin tablet formulations (reference and test) containing 500 mg of levofloxacin. Both the formulations were administered orally as a single dose, separated by a washout period of 1 week. The HPLC method was validated by examining the precision and accuracy for the inter-day and intra-day runs in a linear concentration range of 0.10–10.00 μg/ml. Bioequivalence of two formulations were determined in 12 healthy, Indian, male volunteers in a single-dose, two-period, two-sequence, two-treatment crossover study. The content of levofloxacin in plasma was determined using HPLC with UV detection.

The formulations were compared using the following pharmacokinetic parameters: area under the plasma concentration-time curve (AUC0–t), area under the plasma concentration-time curve from zero to infinity (AUC0–∞), peak plasma concentration (Cmax), and time to reach peak plasma concentration (tmax). The results indicated that there were no statistically significant differences (P > 0.05) between the logarithmically transformed AUC0–∞ and Cmax values of the test and reference formulations. The 90% confidence interval for the ratio of the logarithmically transformed AUC0–t, AUC0–∞ and Cmax were within the bioequivalence limit of 0.8–1.25 and the relative bioavailability of the test formulation was 99.98% of that of the reference formulation.

Key words

Antibacterial - CAS 100986-85-4 - HPLC-UV - Levofloxacin - Pharmacokinetics
 

  • References

  • 1 Tanaka M, Kurata T, Fujisawa C, Oshima Y, Aoki H, Okazaki O et al. Mechanistic study of inhibition of levofloxacin absorption by aluminium hydroxide. Antimicrob Agents Chemother. 1993; 37: 2173-78
    CrossrefPubMedGoogle Scholar
  • 2 Eliopoulos GM, Eliopoulos CT, Hoope DC, Wolfson JS editors. In: Quinolone antibacterial agents. Washington (DC): American Society for Microbiology; 1993: 161-193
    Google Scholar
  • 3 Shen LL, Hoope DC, Wolfson JS editors. In: Quinolone antibacterial agents. Washington (DC): American Society for Microbiology; 1993: 77-95
    Google Scholar
  • 4 Ungerstedt U. Microdialysis: principles and applications for studies in animals and man. J Intern Med. 1991; 230: 365
    CrossrefPubMedGoogle Scholar
  • 5 Müller M. Microdialysis in clinical drug delivery studies. Drug Deliv Rev. 2000; 45: 255-269
    CrossrefPubMedGoogle Scholar
  • 6 Guenter SG, Iven H, Boos C, Bruch HP, Muhl E. Pharmacokinetics of levofloxacin during continuous venovenous he-modiafiltration and continuous venovenous hemofiltration in critically ill patients. Pharmacotherapy. 2002; 22: 175-8
    CrossrefPubMedGoogle Scholar
  • 7 Djabarouti S, Boselli E, Allaouchiche B, Ba B, Nguyen AT, Gordien JM et al. Determination of levofloxacin in plasma, bronchoalveolar lavage and bone tissues by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method. J Chromatogr B. 2004; 799: 165-72
    CrossrefPubMedGoogle Scholar
  • 8 Wong FA, Juzwin SJ, Flor SC. Rapid stereospecific high-performance liquid chromatographic determination of levofloxacin in human plasma and urine. J Pharm Biomed Anal. 1997; 765-71
    PubMedGoogle Scholar
  • 9 Park DJ, Phapale PB, Jang IJ, Cui S, Moon BJ, Kim JE et al. An improved UPLC method for rapid analysis of levofloxacin in human plasma. Chromatographia. 2008; 68: 187-92
    CrossrefPubMedGoogle Scholar
  • 10 Gao X, Yao G, Guo N, An F, Guo X. A simple and and rapid high performance liquid chromatography method to determine levofloxacin in human plasma and its use in a bioequivalence study. Drug Discov Ther. 2007; 2: 136-40
    PubMedGoogle Scholar
  • 11 Liang H, Kays MB, Sowinski KM. Separation of levofloxacin, ciprofloxacin, gatifloxacin, moxifloxacin, trovafloxacin and cinoxacin by high-performance liquid chromatography: application to levofloxacin determination in human plasma. J Chromatogr B Anal Technol Biomed Life Sci. 2002; 772: 53-63
    CrossrefPubMedGoogle Scholar
  • 12 Fish DN, Chow AT. The clinical pharmacokinetic of levofloxacin. Clin Pharmacokinet. 1997; 32: 101-19
    CrossrefPubMedGoogle Scholar
  • 13 Siewert S. Validation of a levofloxacin assay in plasma and dialysate for pharmacokinetic studies. J Pharm Biomed Anal. 2006; 41: 1360-62
    CrossrefPubMedGoogle Scholar
  • 14 Conte Jr JE, Golden JA, McIver M, Zurlinden E. Intrapul-monary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. Int J Antimicrob Agents. 2006; 28: 114-21
    CrossrefPubMedGoogle Scholar
  • 15 Hauschke D, Steinijans V, Diletti E. A distribution free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1990; 30: 37-43
    PubMedGoogle Scholar
  • 16 Schulz HU, Steinijans VW. Striving for standards in bioequivalence assessment: a review. Int J Clin Pharmacol Ther Toxicol. 1992; 30: 51-6
    PubMedGoogle Scholar
  • 17 Farolfi M, Power JD, Rescigno A. On the determination of bioequivalence. Pharmacol Res. 1999; 39: 1-4
    CrossrefPubMedGoogle Scholar
  • 18 Das A, Bhaumik U, Chakraborty US, Sarkar AK, Ghosh A, Bose A et al. Comparative bioavailability study of amisul-pride tablets in healthy indian volunteers. Arzneimittelforschung. 2009; 59 (4) 166-70
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 19 Mandai U, Ganesan M, Pal TK, Jayakumar M, Chattaraj TK, Ray K et al. bioequivalence study of rabeprazole sodium on healthy human subjects. J Ind Med Assoc. 2004; b 102 (1) 26-30
    PubMedGoogle Scholar
  • 20 U. S. Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence Studies for orally Administered Drug Products – General Considerations. Rockville (MD): Center for Drug Evaluation and Research; 2000.
    PubMed
  • 21 Committee for Proprietary Medicinal Products (CPMP). Note for Guidance: Investigation of Bioavailability and Bioequivalence. London: Working Party on the Efficacy of the Medicinal Products; 1991.
    PubMed
  • 22 European Agency for the Evaluation of Medicinal Products. Note for guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/QWP/1401/98; 2002.
    PubMed
  • 23 Nation RL, Sansom LN. Bioequivalence requirements for generic products. Pharmacol Ther. 1994; 62: 41-55
    CrossrefPubMedGoogle Scholar
  • 24 Shah VP, Midha KK, Sing S. Analytical method validation: bioavailability, bioequivalence and pharmacokinetic studies. Eur J Drug Metab Pharmacokinet. 1992; 16: 249-55
    PubMedGoogle Scholar
  • 25 Ritschel WA Drug Intelligenc. In: Handbook of Basic Pharmacokinetics. 4th ed. Hamilton: Hamilton Press; 1992: 588
    Google Scholar